Regeneron Pharmaceuticals, Inc. (REGN) Holdings Lifted by American Century Companies Inc.

American Century Companies Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 917,554 shares of the biopharmaceutical company’s stock after acquiring an additional 20,218 shares during the period. American Century Companies Inc. owned about 0.88% of Regeneron Pharmaceuticals worth $410,257,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of REGN. Janus Henderson Group PLC boosted its holdings in shares of Regeneron Pharmaceuticals by 15,495.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after buying an additional 1,552,948 shares during the period. Jennison Associates LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 74.1% in the 2nd quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock valued at $634,977,000 after buying an additional 550,247 shares during the period. FMR LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after buying an additional 416,192 shares during the period. Old Mutual Global Investors UK Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 500,446.2% in the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after buying an additional 325,290 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 97.8% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 485,336 shares of the biopharmaceutical company’s stock valued at $238,368,000 after buying an additional 239,937 shares during the period. 67.63% of the stock is owned by institutional investors and hedge funds.

REGN has been the subject of several research reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $450.00 price target (up from $405.00) on shares of Regeneron Pharmaceuticals in a report on Monday, July 10th. Credit Suisse Group lowered shares of Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 price target for the company. in a report on Friday, July 14th. Bank of America Corporation reaffirmed a “buy” rating and issued a $593.00 price target (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. BMO Capital Markets reaffirmed a “market perform” rating and issued a $484.00 price target (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $450.00 price objective (up from $400.00) on shares of Regeneron Pharmaceuticals in a research report on Saturday, July 22nd. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $488.57.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up $1.92 during trading on Monday, reaching $410.33. 251,596 shares of the company’s stock traded hands, compared to its average volume of 827,902. The company has a market cap of $43,820.00, a price-to-earnings ratio of 38.38, a PEG ratio of 1.40 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.75 and a quick ratio of 3.21. Regeneron Pharmaceuticals, Inc. has a 12-month low of $325.35 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.82 EPS. sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 13.77 EPS for the current year.

In other news, Director Charles A. Baker sold 2,000 shares of the company’s stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Robert E. Landry sold 526 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total transaction of $248,371.94. Following the completion of the sale, the senior vice president now directly owns 9,099 shares in the company, valued at approximately $4,296,456.81. The disclosure for this sale can be found here. Insiders sold a total of 89,468 shares of company stock worth $42,312,448 in the last three months. Insiders own 10.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Holdings Lifted by American Century Companies Inc.” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/11/06/regeneron-pharmaceuticals-inc-regn-holdings-lifted-by-american-century-companies-inc.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit